{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:37:06Z","timestamp":1784547426516,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":1418,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Intensive Care"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1186\/s13613-022-01036-2","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T02:02:58Z","timestamp":1660701778000},"page":"75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["The use of ICU resources in CAR-T cell recipients: a hospital-wide study"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6834-0624","authenticated-orcid":false,"given":"Sandrine","family":"Valade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Darmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Zafrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Mariotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Lemiale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swann","family":"Bredin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Boissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Rabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Baruchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Madelaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Larghero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Brignier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Lenglin\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Harel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Arnulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Di Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Azoulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1186\/s13613-022-01036-2_bb0010","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol Med"},{"key":"10.1186\/s13613-022-01036-2_bb0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1186\/s13613-022-01036-2_bb0020","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1186\/s13613-022-01036-2_bb0025","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1186\/s13613-022-01036-2_bb0030","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1186\/s13613-022-01036-2_bb0035","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1164\/rccm.201810-1945ED","article-title":"Critical care management of chimeric antigen receptor T cell-related toxicity be aware and prepared","volume":"200","author":"Azoulay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1186\/s13613-022-01036-2_bb0040","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1164\/rccm.202002-0286LE","article-title":"ICU resource use in critically III Patients following chimeric antigen receptor T-cell therapy","volume":"202","author":"Brown","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1186\/s13613-022-01036-2_bb0045","article-title":"Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: a comprehensive review of emerging grading models","author":"Chavez","year":"2019","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1186\/s13613-022-01036-2_bb0050","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bjh.15644","article-title":"Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy","volume":"183","author":"Hay","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1186\/s13613-022-01036-2_bb0055","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/17474086.2019.1585238","article-title":"Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy","volume":"12","author":"Acharya","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"10.1186\/s13613-022-01036-2_bb0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"10.1186\/s13613-022-01036-2_bb0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1186\/s13613-022-01036-2_bb0070","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1186\/s13613-022-01036-2_bb0075","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1186\/s13613-022-01036-2_bb0080","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1186\/s13613-022-01036-2_bb0085","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1186\/s13613-022-01036-2_bb0090","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1186\/s13613-022-01036-2_bb0095","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25502","article-title":"Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy","volume":"86","author":"Gust","year":"2019","journal-title":"Ann Neurol"},{"key":"10.1186\/s13613-022-01036-2_bb0100","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1186\/s13613-022-01036-2_bb0105","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","article-title":"Neurotoxicity associated with CD19-targeted CAR-T cell therapies","volume":"32","author":"Gust","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1186\/s13613-022-01036-2_bb0110","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djz017","article-title":"CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions","author":"Hunter","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1186\/s13613-022-01036-2_bb0115","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1158\/2159-8290.CD-17-1368","article-title":"Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates","volume":"8","author":"Taraseviciute","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1186\/s13613-022-01036-2_bb0120","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1186\/s13613-022-01036-2_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2020.04.020","article-title":"Myeloma CAR-T CRS management with IL-1R Antagonist Anakinra","author":"Jatiani","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1186\/s13613-022-01036-2_bb0130","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1186\/s13613-022-01036-2_bb0135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"10.1186\/s13613-022-01036-2_bb0140","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3026(21)00060-0","article-title":"Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study","volume":"8","author":"Azoulay","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1186\/s13613-022-01036-2_bb0145","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jcrc.2020.10.008","article-title":"Impact of early ICU admission on outcome of critically ill and critically ill cancer patients: a systematic review and meta-analysis","volume":"61","author":"Hourmant","year":"2021","journal-title":"J Crit Care"},{"key":"10.1186\/s13613-022-01036-2_bb0150","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. [Accessed from cited 2019]. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"key":"10.1186\/s13613-022-01036-2_bb0155","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-022-01036-2_bb0160","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1186\/s13613-022-01036-2_bb0165","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/j.clml.2020.12.010","article-title":"Systematic review and Meta-analysis of CD19-specific CAR-T cell therapy in relapsed\/refractory acute lymphoblastic leukemia in the pediatric and young adult population: safety and efficacy outcomes","volume":"21","author":"Aamir","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1186\/s13613-022-01036-2_bb0170","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2021.1881506","article-title":"Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells","author":"Wittmann Dayagi","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1186\/s13613-022-01036-2_bb0175","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the 1st\u00a0year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1186\/s13613-022-01036-2_bb0180","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13613-020-00713-4","article-title":"Expert consensus-based clinical practice guidelines management of intravascular catheters in the intensive care unit","volume":"10","author":"Timsit","year":"2020","journal-title":"Ann Intensive Care"},{"key":"10.1186\/s13613-022-01036-2_bb0185","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13613-018-0383-9","article-title":"Removal of totally implanted venous access ports for suspected infection in the intensive care unit: a multicenter observational study","volume":"8","author":"Lecronier","year":"2018","journal-title":"Ann Intensive Care"},{"key":"10.1186\/s13613-022-01036-2_bb0190","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1182\/bloodadvances.2020002592","article-title":"Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children","volume":"4","author":"Diorio","year":"2020","journal-title":"Blood Adv"},{"key":"10.1186\/s13613-022-01036-2_bb0195","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"key":"10.1186\/s13613-022-01036-2_bb0200","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1097\/RLU.0000000000003870","article-title":"Early 18F-FDG PET flare-up phenomenon after CAR T-cell therapy in lymphoma","volume":"47","author":"Boursier","year":"2022","journal-title":"Clin Nucl Med"},{"key":"10.1186\/s13613-022-01036-2_bb0205","doi-asserted-by":"crossref","first-page":"22427","DOI":"10.18632\/oncotarget.7986","article-title":"Short- and long-term outcomes in onco-hematological patients admitted to the intensive care unit with classic factors of poor prognosis","volume":"7","author":"Faucher","year":"2016","journal-title":"Oncotarget"},{"key":"10.1186\/s13613-022-01036-2_bb0210","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00134-016-4563-5","article-title":"The effects of performance status 1\u00a0week before hospital admission on the outcomes of critically ill patients","volume":"43","author":"Zampieri","year":"2017","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-022-01036-2_bb0215","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jcrc.2014.01.016","article-title":"Impact of Eastern Cooperative Oncology Group Performance Status on hospital mortality in critically ill patients","volume":"29","author":"Park","year":"2014","journal-title":"J Crit Care"},{"key":"10.1186\/s13613-022-01036-2_bb0220","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1200\/JCO.2012.47.2365","article-title":"Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium\u2013a groupe de recherche respiratoire en r\u00e9animation onco-h\u00e9matologique study","volume":"31","author":"Azoulay","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1186\/s13613-022-01036-2_bb0225","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jcrc.2011.06.014","article-title":"Critically ill patients with cancer and sepsis: clinical course and prognostic factors","volume":"27","author":"Rosolem","year":"2012","journal-title":"J Crit Care"},{"key":"10.1186\/s13613-022-01036-2_bb0230","first-page":"159","article-title":"Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials","volume":"68","author":"Yassine","year":"2020","journal-title":"Curr Res Transl Med"},{"key":"10.1186\/s13613-022-01036-2_bb0235","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2018-99-114152","article-title":"Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-cell therapy for relapsed\/refractory large B-cell lymphoma: real world experience","volume":"132","author":"Nastoupil","year":"2018","journal-title":"Blood"},{"key":"10.1186\/s13613-022-01036-2_bb0240","first-page":"92","article-title":"Axicabtagene ciloleucel in the real world: outcomes and predictors of response","volume":"132","author":"Jacobson","year":"2018","journal-title":"Resist Toxic Blood"}],"container-title":["Annals of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-022-01036-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13613-022-01036-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025006338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025006338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-022-01036-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:33:42Z","timestamp":1776670422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2110582025006338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"alternative-id":["S2110582025006338"],"URL":"https:\/\/doi.org\/10.1186\/s13613-022-01036-2","relation":{},"ISSN":["2110-5820"],"issn-type":[{"value":"2110-5820","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of ICU resources in CAR-T cell recipients: a hospital-wide study","name":"articletitle","label":"Article Title"},{"value":"Annals of Intensive Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1186\/s13613-022-01036-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The Author(s) 2022. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}],"article-number":"75"}}